MoonLake Immunotherapeutics

MLTX

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Rock Springs Capital BVF Partners

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 61,700Value: $813K

# Signal Note: Rock Springs Capital initiates MoonLake Immunotherapeutics (MLTX) Rock Springs' $813K entry into MLTX likely reflects conviction in the company's clinical pipeline, potentially including ML001 (being developed for inflammatory conditions) or upcoming data readouts that could de-risk valuation. As a healthcare-focused long/short specialist, Rock Springs' initiation suggests they see asymmetric risk/reward, though the small position size ($813K) indicates either early conviction or sizing appropriate to a micro-cap biotech with execution risk. Monitor for upcoming Phase 2 data or partnership announcements that could validate the thesis.

BVF PartnersNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

OLMA2 funds MIRM2 funds CMPS2 funds GPCR2 funds RVMD2 funds KYMR2 funds MLYS1 fund NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: BVF Partners Initiates $260M Position in MoonLake Immunotherapeutics (MLTX) Lampert's concentrated biotech fund establishing a significant 19.7M share stake signals conviction in MoonLake's lead candidate ML-002, a potential first-in-class CD19/CD20 bispecific for B-cell malignancies currently in clinical development. The ~$260M position size (at current valuation) represents meaningful capital deployment by a manager known for deep due diligence on clinical-stage molecules, likely reflecting confidence in upcoming trial readouts or commercial viability versus existing CAR-T/standard monotherapy options. Key near-term catalysts include clinical data presentations and progression milestones over the next 12-24 months.